Clinical Trial Update: Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SOM230 (pasireotide) in patients with metastatic carcinoid tumors has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumors

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2011-05-06